Medullary Thyroid Cancer Clinical Trial
Official title:
A Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer (MTC)
Verified date | October 2021 |
Source | Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to determine in an exploratory manner the objective overall response rate to ponatinib in the treatment of patients with advanced or metastatic MTC previously treated with cabozantinib or vandetanib who have tumors with rearranged-during-transfection (RET) mutations and have tumors without RET mutations.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 14, 2021 |
Est. primary completion date | June 14, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of localized or metastatic unresectable MTC. - Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as =20 mm with conventional techniques or as =10 mm with spiral computerized tomography (CT) scan. - The last dose of previous therapy targeting RET kinase must be given at least 4 weeks - Previous treatment with cytotoxic chemotherapy, immunotherapy, or radiotherapy are permitted, if the last dose was given at least 4 weeks prior to the first dose of ponatinib - Patient must have failed (progressed on or been intolerant of) prior treatment with cabozantinib or vandetanib. - Age =18 years old - Eastern Cooperative Oncology Group (ECOG) performance status =2 - Normal organ and marrow function as defined below: - Negative pregnancy test for women of childbearing potential or male patients, even if surgically sterilized (i.e., status post-vasectomy), who: - Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or - Agree to completely abstain from heterosexual intercourse - Normal QT interval corrected on screening electrocardiogram (ECG) evaluation, defined as the corrected QT interval by Fredericia (QTcF) of =450 ms. - Ability to understand and the willingness to sign a written informed consent document and follow the guidelines of the clinical protocol including visits for treatment and follow up - Life expectancy of greater than 12 weeks - Available archival tissue or willingness to undergo fresh biopsy if no archival tissue is available. Exclusion Criteria: - Patients who are receiving any other investigational agent. - Patients with brain metastases or spinal cord compression unless they completed radiation therapy =4 weeks prior to the first dose of ponatinib and are stable without steroids or anti-convulsant therapy for =10 days. - Patients who cannot discontinue medications that are known to be associated with Torsades de Pointes. These medications are listed in Attachment 3 - Uncontrolled hypertension (systolic blood pressure >150 or diastolic blood pressure >100 - Significant or active cardiovascular disease within 6 months prior to enrollment - A history of pancreatitis or alcohol abuse - Uncontrolled hypertriglyceridemia (>450 mg/dL) - Major surgery (with the exception of minor surgical procedures, such as catheter placement or tumor biopsy) within 28 days prior to the first dose of ponatinib - Ongoing or active infection including known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV). Testing for these viruses is not required in the absence of a history of infection. - Suffer from any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the safety of the study drug - Evidence of a bleeding diathesis that cannot be corrected with standard therapy or factor replacement - Presence of another primary malignancy within the past 2 years (except for non-melanoma skin cancer or cervical cancer in situ. Prior prostate cancer is also permitted if prostate-specific antigen (PSA) is now undetectable) - Pregnant or lactating - History of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Antonio Fojo | Millennium Pharmaceuticals, Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Total Number of Adverse Reactions | Testing safety and toxicity assessed using CTCAE criteria | 24 months | |
Primary | Objective Response Rate (ORR) | ORR is defined as the proportion of the subjects in the analysis population who have a complete response (CR) or partial response (PR). Responses are based on assessments per RECIST. | 24 months | |
Secondary | Progression-Free Survival (PFS) | PFS is defined as the time from the first day of trial treatment to the first documented disease progression per the Kaplan-Meier curve. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03643055 -
18F-Fluorocholine PET/CT in Medullary Thyroid Cancer
|
||
Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06277180 -
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
|
N/A | |
Withdrawn |
NCT04760288 -
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
|
Phase 3 | |
Not yet recruiting |
NCT06079723 -
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
|
||
Recruiting |
NCT01739634 -
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03157128 -
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
|
Phase 1/Phase 2 | |
Completed |
NCT02856347 -
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
|
N/A | |
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04280081 -
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
|
Phase 2 | |
Not yet recruiting |
NCT06292988 -
Predictive Factors for Medullary Thyroid Cancer Aggressiveness
|
||
Completed |
NCT01757470 -
Vandetanib Risk Minimisation Effectiveness
|
N/A | |
Recruiting |
NCT05830500 -
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
|
Phase 4 | |
Recruiting |
NCT03899792 -
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT01660984 -
Natural History Study of Children and Adults With Medullary Thyroid Cancer
|
||
Terminated |
NCT02363647 -
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer
|
N/A | |
Terminated |
NCT00582712 -
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT06141369 -
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
|
N/A | |
Completed |
NCT06243965 -
Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?
|
||
Active, not recruiting |
NCT01298323 -
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
|
Phase 3 |